AGENUS Aktie

 

Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues....

Agenus bets on BOT+BAL in MSS mCRC, and the phase III BATTMAN trial determines whether early survival signals translate into a pivotal win....

Agenus turns early physician demand for BOT+BAL into revenues and real-world data, testing its launch strategy before formal approval....

AGEN trades below peers on sales multiples, but BOT+BAL's promise is offset by funding needs, dilution risk and a going-concern warning....

Iovance's commercial momentum and expanding Amtagvi pipeline make it appear better positioned than Agenus despite higher valuation....

AGEN advances BOT/BAL into phase III for MSS colorectal cancer as survival data and global access efforts shape its next growth phase....

Agenus' shares slide after weak Q1 results, but BOT/BAL phase III progress, survival data and Zydus backing keep long-term growth hopes alive....

Agenus (AGEN) delivered earnings and revenue surprises of -51.43% and -73.95%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Authorized access interest continues to expand across regions Phase 3 BATTMAN trial commenced patient enrollment in April 2026, advancing BOT+BAL into pivotal evaluation Zydus collaboration closed in January, delivering strategic capital, strengthening Agenus' balance sheet and securing dedicated U.S. biologics manufacturing capacity Agenus continues to align operating priorities around BOT+BAL, financial discipline and commercial readiness SEC concluded its investigation in May 2026 with no enforcement action recommended; Related putative securities class action dismissed in its entirety by the U.S. District Court for the District of Massachusetts in March 2026 LEXINGTON, Mass.--(BUSINESS WIRE)--$AGEN #BATTMAN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today reported financial results for the first quarter ended March 31, 2026, and provided an operational update on botensilimab plus balstilimab (BOT+BAL), the Company's lead clinical program and one of the most clinically advan...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Investors need to pay close attention to AGEN stock based on the movements in the options market lately....

LEXINGTON, Mass.--(BUSINESS WIRE)--$AGEN #AGEN--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its first quarter 2026 financial results before the market opens on Monday, May 11, 2026. Agenus plans to host a webcast in June, in conjunction with its Annual Meeting of Shareholders, to spotlight key strategic priorities, upcoming data milestones, and progress across the global botensilimab (BOT) and balstilimab (BAL) development program. About Agenus Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, ...

Agenus (AGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

Does Agenus (AGEN) have what it takes to be a top stock pick for momentum investors? Let's find out....

Agenus (AGEN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions....

Agenus (AGEN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service....

Here is how Agenus (AGEN) and Ensign Group (ENSG) have performed compared to their sector so far this year....

Agenus (AGEN) delivered earnings and revenue surprises of +144.27% and +17.54%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?...